Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - cefuroxime axetil - film coated tablet - 500 base milligrams - second-generation cephalosporins

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - cefuroxime axetil - film coated tablet - 250 base milligrams - second-generation cephalosporins

Marekani - Kiingereza - NLM (National Library of Medicine)

samson medical technologies, l.l.c. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime sodium 75 g

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 1.5 gram(s) - second-generation cephalosporins; cefuroxime

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 750 milligram(s) - second-generation cephalosporins; cefuroxime

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection - 250 milligram(s) - second-generation cephalosporins; cefuroxime

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection - 750 milligram(s) - second-generation cephalosporins; cefuroxime

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection/infusion - 1500 milligram(s) - second-generation cephalosporins; cefuroxime

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; calcium carbonate; microcrystalline cellulose; calcium stearate; croscarmellose sodium; purified water; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 601.43 mg - tablet, film coated - excipient ingredients: crospovidone; calcium stearate; purified water; colloidal anhydrous silica; calcium carbonate; microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.